G1 Therapeutics (GTHX) Given Daily News Sentiment Score of 0.27
News headlines about G1 Therapeutics (NASDAQ:GTHX) have been trending positive on Saturday, Accern Sentiment reports. The research group rates the sentiment of press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. G1 Therapeutics earned a daily sentiment score of 0.27 on Accern’s scale. Accern also gave news coverage about the company an impact score of 46.4826827369946 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
A number of equities research analysts recently weighed in on GTHX shares. ValuEngine raised G1 Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. HC Wainwright started coverage on G1 Therapeutics in a research report on Tuesday, May 29th. They set a “buy” rating and a $61.00 target price on the stock. Needham & Company LLC lifted their target price on G1 Therapeutics from $42.00 to $60.00 and gave the stock a “buy” rating in a research report on Friday, May 18th. BidaskClub downgraded G1 Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, May 31st. Finally, Zacks Investment Research raised G1 Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, May 15th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $58.00.
Shares of GTHX opened at $58.06 on Friday. The stock has a market cap of $1.94 billion, a price-to-earnings ratio of -16.26 and a beta of -1.59. G1 Therapeutics has a 12 month low of $16.26 and a 12 month high of $64.83.
In other G1 Therapeutics news, major shareholder Clay Thorp sold 800,000 shares of the firm’s stock in a transaction dated Wednesday, May 30th. The shares were sold at an average price of $48.00, for a total transaction of $38,400,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Mark A. Velleca sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, August 15th. The stock was sold at an average price of $55.88, for a total transaction of $279,400.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 829,545 shares of company stock valued at $39,843,391. Corporate insiders own 15.92% of the company’s stock.
G1 Therapeutics Company Profile
G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer in the United States. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2a clinical trials for patients with small cell lung cancer, as well as Phase 2 clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; G1T38, an oral CDK4/6 inhibitor that is Phase 1b/2a clinical trials for the treatment of breast cancer; and G1T48, an oral selective estrogen receptor degrader, which is in preclinical development.
Further Reading: Price to Earnings Ratio (PE)
Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.